Efficacy and Safety Assessment of Beltavac® With Polymerized Extract of HDM

Inclusion Criteria: * Written informed consent, signed and duly dated. * Man or woman between 12 and 65 years old (both included). * Patient with moderate or severe symptoms of persistent rhinitis according to the ARIA Guide, associated or not with well or partially controlled asthma according to the GEMA 5.0 Guide. * Confirmation of sensitization to DPT or DF with a positive prick test (mean papule diameter greater than or equal to 3 mm) with a commercial standardized allergenic extract and a serum extract-specific IgE value of class 3 or higher (\> 3.5 kU / L) within the 6 months prior to the study. * Negative pregnancy test. * Nasal symptom and medication combined scale score ≥ 1.5 during the screening phase. Exclusion Criteria: * Concomitant sensitization to allergens other than dust mites if clinically relevant symptoms are anticipated that may interfere with study evaluation periods at the discretion of the investigator. * Poorly controlled asthma according to the GEMA 5.0 guideline * Severe asthma, that is, those who during the last months have controlled their asthma according to therapeutic step 5-6 of the GEMA 5.0 guideline. * Autoimmune diseases or immunodeficiency. * Malignant neoplasms, serious cardiovascular disease, serious mental illness or other relevant chronic diseases that may interfere with the results of the study. * Clinical history of anaphylaxis with cardio / respiratory symptoms. * Hypersensitivity to any of the excipients of the investigational product. * Immunosuppressive medication during the last 6 months before the inclusion of patients and until the end of the study. * Treatment with beta-blockers during the study. * Patients who have previously received immunotherapy with allergenic dust mite extract or other extracts and have failed within the last 5 years. * Patients with immunotherapy with allergens other than dust mites during the study period. * Patients who receive any other vaccine one week before the start of treatment or awaiting the second dose of vaccine against COVID-19. * Pregnant or nursing patients.